BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical
company utilizing artificial intelligence approaches to develop
transformative medicines in neuroscience and immuno-oncology, today
announced that it will host a virtual Neuroscience R&D Day from
1:00 to 2:30 p.m. ET on Tuesday, Dec. 12, 2023.
Vimal Mehta, Ph.D., Chief Executive Officer, Frank Yocca, Ph.D.,
Chief Scientific Officer, and other members of the Company’s
R&D leadership team will discuss BioXcel Therapeutics’ R&D
strategy and provide an overview of the proposed development
program for BXCL502, a novel, investigational, non-antipsychotic
anti-stress agent for the potential treatment of chronic agitation
in dementia. Further, the Company will discuss its unique AI-driven
approach to identify emerging development candidates, such as
investigational BXCL503, to potentially treat Alzheimer’s
disease-related symptoms unrelated to agitation.
In addition, the presentation will feature two neuropsychiatry
experts:
- Dr, Jeffrey Cummings, M.D.
Sc.D.:(HC): The
Neuropsychiatric Inventory: Measuring Agitation Relief in
Alzheimer’s DiseaseDr. Jeffrey Cummings is Research Professor in
the Department of Brain Health and Director of the Chambers-Grundy
Center for Transformative Neuroscience at the University of Nevada,
Las Vegas. He previously served as Founding Director of the
Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas,
Director of the Mary S. Easton Center for Alzheimer’s Disease
Research, and Director of the Deane F. Johnson Center for
Neurotherapeutics, both at UCLA. A world-renowned Alzheimer’s
researcher and leader of clinical trials, Dr. Cummings has been
recognized with the American Geriatrics Society’s Henderson Award,
the national Alzheimer’s Association’s Ronald and Nancy Reagan
Research Award, and the American Association of Geriatric
Psychiatry’s Distinguished Scientist Award. He has published nearly
900 articles and 44 books devoted to neuroscience, Alzheimer’s
disease, and clinical trials.
- Dr. Sandra Comer,
Ph.D.: BXCL501 as a Potential
Treatment for Opioid WithdrawalDr. Sandra Comer is Principal
Investigator of the National Institute on Drug
Abuse (NIDA)-funded trial of investigational BXCL501 for
potential withdrawal treatment of patients diagnosed with opioid
use disorder and Professor of Neurobiology in the Department of
Psychiatry at Columbia University. She is also Director of the
Opioid Laboratory in the Division on Substance Use Disorders. Her
research focuses on the clinical testing of medications for
treating opioid use disorders, devices for treating opioid
overdose, methods to maximize the use of naloxone by opioid users,
and evaluations of the comparative abuse liability of prescribed
pain medications. Dr. Comer served as President of the College on
Problems of Drug Dependence (CPDD), the longest-standing scholarly
society in the U.S. devoted to research on substance use disorders,
and is currently CPDD’s Public Policy Officer. She joined the
Expert Advisory Panel on Drug Dependence for the World Health
Organization and has 190 publications on substance use
disorders.
Event AccessTo access the virtual R&D Day
presentation, please dial 877-407-5795 (domestic) or 201-689-8722
(international). A live webcast and presentation materials will be
available on the Investors section of the corporate
website, bioxceltherapeutics.com, and a webcast replay
will be available through March 12, 2024.
BioXcel Therapeutics may use its website as a distribution
channel of material information about the Company. Financial and
other important information is routinely posted on and accessible
through the Investors sections of its website at
bioxceltherapeutics.com. In addition, you may sign up to
automatically receive email alerts and other information about the
Company by visiting the “Email Alerts” option under the News/Events
section of the Investors & Media website section and submitting
your email address.
About BXCL501 In indications other than those
approved by the U.S. Food and Drug Administration (FDA) as IGALMI™
(dexmedetomidine) sublingual film, BXCL501 is an investigational,
proprietary, orally dissolving film formulation of dexmedetomidine,
a selective alpha-2 adrenergic receptor agonist. BioXcel
Therapeutics believes that BXCL501 potentially targets an important
mediator of agitation, and the Company has observed anti-agitation
results in multiple clinical trials across several neuropsychiatric
disorders. BXCL501 is under investigation by BioXcel Therapeutics
for the acute treatment of agitation associated with dementia due
to probable Alzheimer’s disease and for the acute treatment of
agitation associated with bipolar I or II disorder or schizophrenia
in the at-home setting. The safety and efficacy of BXCL501 for
these investigational uses have not been established. BXCL501 has
been granted Breakthrough Therapy designation by the FDA for the
acute treatment of agitation associated with dementia and Fast
Track designation for the acute treatment of agitation associated
with schizophrenia, bipolar disorders, and dementia.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a
biopharmaceutical company utilizing artificial intelligence to
develop transformative medicines in neuroscience and
immuno-oncology. The Company’s drug re-innovation approach
leverages existing approved drugs and/or clinically validated
product candidates together with big data and proprietary machine
learning algorithms to identify new therapeutic indications.
For more information, please
visit bioxceltherapeutics.com.
Forward-Looking Statements This press release
includes “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. We intend such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act of 1933, as amended (the “Securities Act”)
and Section 21E of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”). All statements contained in this press
release other than statements of historical fact should be
considered forward-looking statements, including, without
limitation, the date, time and content of the Company’s R&D
Day, its proposed development programs, and the potential uses of
its product candidates. When used herein, words including
“anticipate,” “believe,” “can,” “continue,” “could,” “designed,”
“estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,”
“plan,” “possible,” “potential,” “predict,” “project,” “should,”
“target,” “will,” “would” and similar expressions are intended to
identify forward-looking statements, though not all forward-looking
statements use these words or expressions. In addition, any
statements or information that refer to expectations, beliefs,
plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking. All forward-looking
statements are based upon the Company’s current expectations and
various assumptions. The Company believes there is a reasonable
basis for its expectations and beliefs, but they are inherently
uncertain. The Company may not realize its expectations, and its
beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various important factors, including,
without limitation, the important factors discussed under the
caption “Risk Factors” in its Quarterly Report on Form 10-Q for the
quarterly period ended September 30, 2023, as such factors may be
updated from time to time in its other filings with the SEC, which
are accessible on the SEC’s website at www.sec.gov. These and other
important factors could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management’s estimates as of the date of this press release. While
the Company may elect to update such forward-looking statements at
some point in the future, except as required by law, it disclaims
any obligation to do so, even if subsequent events cause our views
to change. These forward-looking statements should not be relied
upon as representing the Company’s views as of any date subsequent
to the date of this press release.
Contact Information
Corporate
BioXcel TherapeuticsErik
Kopp1.203.494.7062ekopp@bioxceltherapeutics.com
Investor Relations
BioXcel TherapeuticsBrennan
Doyle1.475.355.8462bdoyle@bioxceltherapeutics.com
Media
Russo Partners David
Schull T: 858-717-2310 David.schull@russopartnersllc.com Scott
Stachowiak T: 646-942-5630 Scott.stachowiak@russopartnersllc.com
Source: BioXcel Therapeutics, Inc.
*IGALMI is a trademark of BioXcel Therapeutics, Inc. BT
BIOXCEL THERAPEUTICS is a registered trademark of BioXcel
Therapeutics, Inc. All other
trademarks are the properties of their respective
owners. Copyright © 2023, BioXcel
Therapeutics, Inc. All rights reserved.
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2023 to Apr 2024